Presentations by Event

Presented at SCI-RSC Symposium on Antimicrobial Drug Discovery, November 2021

Discovery of ETX0462, a novel non-β-lactam PBP inhibitor to treat Gram-negative infections, including MDR Pseudomonas aeruginosa

Thomas Durand-Reville

Program(s): etx0462

Presented at ECCMID, July 2021

In Vitro Activity of Sulbactam-Durlobactam against Recent Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

Sarah McLeod, Samir Moussa, Meredith Hackel and Alita Miller

Program(s): durlobactam (etx2514)

Presented at World Microbe Forum, June 2021

ETX0462, A Novel Non-β-lactam PBP Inhibitor, Is Bactericidal Against Gram-Negative Pathogens

Thomas Durand-Reville

Program(s): etx0462

ETX0462 Inhibits Penicillin-binding Protein 3 of Pseudomonas aeruginosa and Escherichia coli

Adam B. Shapiro, Sarah M. McLeod, Samir H. Moussa and Alita A. Miller

Program(s): etx0462

The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Retains Potent Antibacterial Activity Across Isogenic Panels of Gram-negative Resistant Determinants

Sarah McLeod, Nicole Carter, Ramkumar Iyer, Samir Moussa and Alita Miller

Program(s): etx0462

Evaluation of the Pharmacokinetics/pharmacodynamics (PK/PD) of the Novel Diazabicyclooctane(DBO) ETX0462 Against Pseudomonas aeruginosa Infections, Including MDR Strains

John O'Donnell, Angela Tanudra, April Chen, Dan Hines, Ruben Tommasi, Alita Miller, and Thomas Durand-Reville

Program(s): etx0462

ETX0462 is a Novel PBP Inhibitor with Potent Activity against Recent, Global, Gram-Negative Clinical Isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, and Alita Miller

Program(s): etx0462

The Discovery of the Novel Diazabicyclooctane (DBO) ETX0462: A Single Antibacterial Agent to Treat Gram-negative Infections, Including MDR Pseudomonas aeruginosa

Thomas Durand-Reville, Mark Sylvester, Janelle Comita, Frank Wu, Xiaoyun Wu, Jing Zhang, Jan Romero, Satenig Guler, Camilo Velez-Vega, Adam Shapiro, Nicole Carter, April Chen, Ramkumar Iyer, Samir Moussa, Sarah McLeod, Alita Miller, John O’Donnell and Ruben Tommasi

Program(s): etx0462

The Novel, Non-β-lactam PBP Inhibitor, ETX0462, Has Potent Activity Against Biothreat Pathogens In Vitro and In Vivo

Ruben Tommasi, Henry Heine, George Drusano, Jason Cummings, Richard Slayden, Thomas Durand-Reville, John O’Donnell, and Alita Miller

Program(s): etx0462

Outer Membrane Permeability and Efflux Do Not Limit Antibacterial Activity of Sulbactam-Durlobactamin Acinetobacter baumannii

Nicole M. Carter, Samir H. Moussa, Sarah M. McLeod, Alita A. Miller and Ramkumar Iyer

Program(s): durlobactam (etx2514)

Effect Of Susceptibility Testing Conditions On The In Vitro Antibacterial Activity Of Sulbactam-Durlobactam

Nicole Carter, Sarah McLeod and Alita Miller

Program(s): durlobactam (etx2514)

ETX0462, a Novel Non β-lactam PBP Inhibitor, Is Bactericidal Against Gram Negative Pathogens with a Low Propensity for Mutant Generation

Nicole Carter, Sarah McLeod, Samir Moussa and Alita Miller

Program(s): etx0462

The β-lactamase inhibitor ETX1317 restores the activity of cefpodoxime against recent (2017 2019), geographically diverse drug resistant Enterobacterales isolates

Sarah McLeod, Michael Huband, Jennifer Thompson, John Mueller and Alita Miller

Program(s): etx0282

Sulbactam-Durlobactam MIC and Disk Diffusion Quality Control Ranges Using A CLSI M23-A4 Study Design

Sarah McLeod, Nicole Carter and Alita Miller

Program(s): durlobactam (etx2514)